In The Lancet Infectious Diseases, Elizabeth Byrne and colleagues1 report the biological mechanism by which injectable progestin-only contraceptives, such as depot medroxyprogesterone acetate (DMPA) and norethindrone enanthate (NET-EN), or endogenous progesterone might act to increase the risk of HIV acquisition in women. They report that HIV-negative injectable progestin-only contraceptive users had a 3·92 times higher frequency of cervical HIV target cells than women using no long-term contraceptive (p=0·0241), and women using no long-term contraceptive in the luteal phase of the menstrual cycle (a naturally high-progestin state) also had a 3·25 times higher frequency of cervical target cells than those in the lower-progestin follicular phase (p=0·0488)…

Source: The Lancet Infectious Diseases

 

Related post

Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study

Comment: The role of progestins in HIV acquisition in young women